Zhitong Finance App News, Yiteng Jiahe (06998) announced that on November 17, 2026, Yiteng Pharmaceutical (Zhuhai), an indirect wholly-owned subsidiary of the Company, signed an agreement with Taizhou Yiteng Jingang to entrust Taizhou Yiteng Jingang's facilities to carry out process technology transfer, regulatory reporting support, and commercial production.
According to the agreement, Yiteng Pharmaceutical (Zhuhai) will also provide the equipment required for commercial production of products, and Taizhou Yiteng Jingang will purchase such equipment by deducting a lower double-digit percentage of the total purchase price including tax payable by Yiteng Pharmaceuticals (Zhuhai) for each unit of commercial product from the product purchase payment until the total purchase price of such equipment is fully offset.
The Board of Directors believes that the conclusion of the agreement is in line with the Group's business needs to promote localized technology transfer, registration and commercial production of related products, and to establish a stable and controlled domestic production and supply system. The technology transfer and commercialization arrangements under the agreement complement each other commercially, and together form an overall cooperation framework for the Group to allocate dedicated production capacity for related products, promote technology transfer, and ensure continuous supply. The main reasons and anticipated benefits of the transaction under the agreement are as follows:
1. Improve supply security through dedicated production capacity that matches the characteristics of product demand. The Group's existing production base currently does not have the conditions for co-production of products, so it is necessary to appoint a qualified third party contractor to undertake commercial production of the product. As far as demand characteristics are concerned, considering the number of patients, treatment cycle and batch size requirements, there are relatively few production batches per year; however, Rujianing is in a stage of rapid growth, making market demand forecasting more challenging. These characteristics require contractors to maintain production line availability and scheduling priorities when production batches are small, while retaining the flexibility to rapidly expand production scale and delivery when demand increases. Through equipment configuration, contractor facility modifications and commercial production arrangements under the agreement, a dedicated production line will be established for the product, and agreements will be made on capacity reservation, procurement forecasting, contingency planning and supply guarantee. These complementary arrangements enable production capacity to match the respective demand characteristics of the two products, reduce the risk of production capacity being occupied by orders from other customers and additional costs due to order adjustments, improve the predictability of supply plans, and guarantee the continuous commercial supply of products.
2. Strengthen quality management and compliance risk control. The products are all oral solid dosage forms, involving process verification, cleaning verification, co-production control and quality release. Taizhou Yiteng Jingang has experience in the development, registration and commercial production of relevant dosage forms, has complete licenses and qualifications, and has a perfect quality management system. Specialized production lines can provide more targeted arrangements for production, hygiene and quality control, thereby reducing the complexity of quality management caused by the risk of cross-contamination and confusion involved in multi-product co-line production.
3. Improve technology transfer, production and supply chain coordination. Entrusting a single trustee to undertake technology transfer, verification, registration support and commercial production within the agreed framework, and equipped with special equipment and production lines can reduce coordination costs, document connection problems and information transmission risks.
4. Support project implementation through equipment repurchase. The arrangement aims to establish a dedicated production line for the product, in line with current practices in the pharmaceutical CDMO/contract manufacturing industry. The equipment repurchase arrangement links the recovery of the total purchase price of the equipment to actual production and sales volume to ensure that the deduction schedule matches the life of the equipment. Until the total purchase price of the equipment is fully deducted, the Group retains ownership of the relevant equipment assets, provides a means for asset recovery, and reduces the risk of equipment idleness and impairment. The arrangement helps to consolidate long-term cooperation between the contracting parties and ensures the continuity and stability of production and supply.
5. Protect core technology and intellectual property rights. Taizhou Yiteng Jingang has established a long-term foundation of cooperation with the Group. Special production line arrangements, combined with relatively fixed production, quality and technical personnel, help narrow the scope of access and circulation of technical information. The agreement also stipulates confidentiality obligations, restrictions on the use and storage of technical information, personnel management, liability for breach of contract and inspection rights.
6. Comprehensive evaluation criteria. The Group conducted a comprehensive assessment of a number of candidate CDMO institutions, covering capacity, compliance, supply assurance, co-production risks, technology transfer and commercialization offers. Other candidate CDMO agencies generally rely on shared production lines to serve multiple customers, while Taizhou Yiteng Jingang proposed the establishment of a dedicated production line dedicated to products, which has structural advantages in terms of capacity guarantee, supply safety, and reduction of the risk of cross-contamination.
7. Verifiable risk allocation and pricing fairness guarantee. The Group will review relevant pricing with reference to cost composition, procurement volume, comparable market data or third party data (if applicable) and the results of independent and fair negotiations, and reserves the right to review material cost components and related financial records.